TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05470855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
Study: NCT06056362

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-LM3
Description: 40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-LM3
Description: 40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3
Description: All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
Study: NCT05397340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters
Study: NCT06287086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL-101 autologous hematopoietic stem and progenitor cells injection
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Study: NCT06547671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Employment of a confort room to help in anxiety and agitation moments.
Description: Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
Study: NCT06258733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay-led FL workshops
Description: Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert-led workshops
Description: Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
Study: NCT05913986

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LUDLEV®300 mg/46.2 mg
Description: LUDLEV®300 mg/46.2 mg once day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo treatment (maltodextrin), once daily (u.i.d)
Study: NCT05975632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Self testing Potassium device
Description: Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test
Study: NCT04129125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoom Reperfusion System
Description: Thrombectomy
Study: NCT06408597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Infusion
Description: Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mannitol Infusion
Description: Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Regimen
Description: Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Regimen
Description: Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Regimen
Description: Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status.
Study: NCT04953286

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of visual acuity
Description: ETDRS and Parinaud scale

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of visual acuity
Description: ETDRS and Parinaud scale

Intervention type: OTHER
Group type: OTHER
Intervention: Interferometry
Description: Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Intervention type: OTHER
Group type: OTHER
Intervention: Interferometry
Description: Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus

Intervention type: OTHER
Group type: OTHER
Intervention: Samples of basal tears
Description: Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

Intervention type: OTHER
Group type: OTHER
Intervention: Samples of basal tears
Description: Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary

Intervention type: OTHER
Group type: OTHER
Intervention: Central corneal sensitivity
Description: Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

Intervention type: OTHER
Group type: OTHER
Intervention: Central corneal sensitivity
Description: Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)

Intervention type: OTHER
Group type: OTHER
Intervention: Slit lamp examination and undilated fundus
Description: Slit lamp examination and undilated fundus

Intervention type: OTHER
Group type: OTHER
Intervention: Slit lamp examination and undilated fundus
Description: Slit lamp examination and undilated fundus

Intervention type: OTHER
Group type: OTHER
Intervention: Conjunctival impression
Description: Conjunctival impression with anesthetic instillation

Intervention type: OTHER
Group type: OTHER
Intervention: Conjunctival impression
Description: Conjunctival impression with anesthetic instillation

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the corneal innervation
Description: Contact corneal confocal microscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the corneal innervation
Description: Contact corneal confocal microscopy
Study: NCT04699825

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular and immunological changes
Description: performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and immunological changes
Description: performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
Study: NCT05912985

Intervention type: OTHER
Intervention: different oxygenation methods
Description: Different oxygenation methods are used in bronchoscopy procedures under sedation.

Intervention type: OTHER
Intervention: different oxygenation methods
Description: Different oxygenation methods are used in bronchoscopy procedures under sedation.

Intervention type: OTHER
Intervention: different oxygenation methods
Description: Different oxygenation methods are used in bronchoscopy procedures under sedation.
Study: NCT04400981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical therapy
Description: Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction.
Study: NCT06295497

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung-SIGHT
Description: * The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up.
Study: NCT06365450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participants will receive hybrid educational intervention on breast and cervical cancer
Study: NCT05998330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiverPAL
Description: The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
Study: NCT04170101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep NMB
Description: 0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
Study: NCT05573100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
Study: NCT06486727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redtouch
Description: 675-nm laser
Study: NCT05254717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counselling
Description: intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
Study: NCT05425225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level LASER therapy
Description: Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
Study: NCT06372106

Intervention type: DEVICE
Intervention: SaO2 Sampling
Description: CO-Oximetry analysis of arterial blood samples

Intervention type: DEVICE
Intervention: SaO2 Sampling
Description: CO-Oximetry analysis of arterial blood samples

Intervention type: DEVICE
Intervention: SaO2 Sampling
Description: CO-Oximetry analysis of arterial blood samples
Study: NCT05393622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
Description: Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
Study: NCT04119440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S_DF1 - Low Dose
Description: Administrations of the low dose via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S_DF1 - High Dose
Description: Administrations of the high dose via the intramuscular route

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrations of placebo via the intramuscular route
Study: NCT05085561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REC-994
Description: REC-994 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REC-994
Description: REC-994 200 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study: NCT05771025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Patients in the hepatectomy group receive liver resection.
Study: NCT05590143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet [Farxiga]
Description: One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
Study: NCT05632718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
Study: NCT05199857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE BEAT Group Wellness Education program - phase 1
Description: Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Club Home Exercise program - phase 2
Description: This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
Study: NCT05605288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Coronary angiography +/- percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Coronary angiography +/- percutaneous coronary intervention
Study: NCT05514171

Intervention type: PROCEDURE
Intervention: Neoadyuvant therapy
Description: Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
Study: NCT06108453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Sodium
Description: Methotrexate oral administration alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Sodium
Description: Methotrexate oral administration alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Co-administration of methotrexate and rifampicin